AveXis – $95 Million IPO

Cooley advised AveXis on its $95 million initial public offering. The company now trades on the Nasdaq Global Select Market under the symbol "AVXS."

AveXis is a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases.

Related Contacts
Div Gupta Partner, New York
Darren DeStefano Partner, Reston
Madison Jones Associate, Washington, DC
Alex Weaver Associate, Washington, DC
Ivor Elrifi Partner, New York
Katherine Miller Associate, Boston
Natasha Leskovsek Partner, Washington, DC
Phil Mitchell Partner, New York
Megan Arthur Schilling Partner, San Diego
Dani Nazemian Associate, San Diego
Susan Cooper Philpot Partner, San Francisco
Kenneth Krisko Partner, Reston
Jennifer Raab Associate, Palo Alto
Francis Wheeler Partner, Colorado